KR20250109234A - Ddr1 키나아제 저해제로서의 화합물 및 의약 - Google Patents

Ddr1 키나아제 저해제로서의 화합물 및 의약

Info

Publication number
KR20250109234A
KR20250109234A KR1020257020743A KR20257020743A KR20250109234A KR 20250109234 A KR20250109234 A KR 20250109234A KR 1020257020743 A KR1020257020743 A KR 1020257020743A KR 20257020743 A KR20257020743 A KR 20257020743A KR 20250109234 A KR20250109234 A KR 20250109234A
Authority
KR
South Korea
Prior art keywords
carbonyl
indazol
azetidin
ethan
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257020743A
Other languages
English (en)
Korean (ko)
Inventor
고스케 하시모토
쥰시 아사다
메이 스가노마타
요헤이 혼다
요타 츠즈키
게이지 고스기
Original Assignee
니뽄 신야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니뽄 신야쿠 가부시키가이샤 filed Critical 니뽄 신야쿠 가부시키가이샤
Publication of KR20250109234A publication Critical patent/KR20250109234A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020257020743A 2022-11-21 2023-11-20 Ddr1 키나아제 저해제로서의 화합물 및 의약 Pending KR20250109234A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2022-185827 2022-11-21
JP2022185827 2022-11-21
PCT/JP2023/041679 WO2024111560A1 (ja) 2022-11-21 2023-11-20 Ｄｄｒ１キナーゼ阻害剤としての化合物および医薬

Publications (1)

Publication Number Publication Date
KR20250109234A true KR20250109234A (ko) 2025-07-16

Family

ID=91195603

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020257020743A Pending KR20250109234A (ko) 2022-11-21 2023-11-20 Ddr1 키나아제 저해제로서의 화합물 및 의약

Country Status (12)

Country Link
EP (1) EP4624465A1 (https=)
JP (1) JP7823226B2 (https=)
KR (1) KR20250109234A (https=)
CN (1) CN120569374A (https=)
AU (1) AU2023386923A1 (https=)
CL (1) CL2025001435A1 (https=)
CO (1) CO2025006877A2 (https=)
IL (1) IL320735A (https=)
MX (1) MX2025005556A (https=)
PE (1) PE20251709A1 (https=)
TW (1) TW202430151A (https=)
WO (1) WO2024111560A1 (https=)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2017A (en) 1841-03-26 The graphic co
IL165863A0 (en) * 2002-06-24 2006-01-15 Schering Corp Indole derivatives useful as histamine H3 antagonists
DE10337184A1 (de) * 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
EP1965862A2 (en) * 2005-12-21 2008-09-10 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
SMT201800070T1 (it) 2012-12-19 2018-03-08 Celgene Quanticel Res Inc Inibiorti di istone demetilasi
US9199945B2 (en) 2013-06-21 2015-12-01 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
US9598419B1 (en) 2014-06-24 2017-03-21 Universite De Montreal Imidazotriazine and imidazodiazine compounds
CN108276388B (zh) * 2017-03-10 2020-01-14 成都医学院 1h-吲哚类衍生物及其用途
KR102297587B1 (ko) * 2018-08-07 2021-09-06 재단법인 대구경북첨단의료산업진흥재단 치환된 n-헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
KR102886315B1 (ko) 2018-12-21 2025-11-14 닛산 가가쿠 가부시키가이샤 고분자 및 금속미립자를 포함하는 무전해도금하지제
WO2020210642A1 (en) * 2019-04-10 2020-10-15 Camp4 Therapeutics Corporation Methods and compositions for treating urea cycle disorders
US12403137B2 (en) 2019-10-28 2025-09-02 Tango Therapeutics, Inc. Compounds and methods of use
WO2022051569A1 (en) * 2020-09-04 2022-03-10 Ikena Oncology, Inc. Substituted 3-piperidinyl-pyrrolo[2,3-b]pyridines and related compounds and their use in treating medical conditions
WO2022140290A1 (en) * 2020-12-21 2022-06-30 Cytokinetics, Inc. Pyrazole derivatives useful as nampt modulators

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
Almasi-Nasrabadi et al., Gene. 2019 Jun 5; 700: 17-22.
Azizi et al., J Cell Physiol. 2019 Nov; 234(11): 19539-19552.
Azreq et al., Oncotarget. 2016 Jul 19; 7(29): 44975-44990.
Barisione et al., Blood Cancer J. 2017 Jan 6; 6(1): e513.
Cader et al., Blood. 2013 Dec 19; 122(26): 4237-45.
Favreau et al., Cancer Med. 2014 Apr; 3(2): 265-72.
Franco et al., Circ Res. 2008 May 23; 102(10): 1202-11.
Gross et al., Matrix Biol. 2010 Jun; 29(5): 346-56.
Guo et al., Exp Ther Med. 2019 Mar; 17(3): 1593-1600.
Hahn et al., Int J Mol Med. 2010 May; 25(5): 785-91.
Han et al., PLoS One. 2020 Apr 24; 15(4): e0231501.
Heinzelmann-Schwarz et al., Clin Cancer Res. 2004 Jul 1; 10(13): 4427-36.
Kerroch et al., FASEB J. 2012 Oct; 26(10): 4079-91.
Le et al., Front Cell Dev Biol. 2020 Jun 3; 8: 412.
Matsuyama et al., J Immunol. 2005 May 15; 174(10): 6490-8.
Miao et al., Med Oncol. 2013; 30(3): 626.
Moll et al., J Transl Med. 2018 Jun 1; 16(1): 148.
Ram et al., J Neurooncol. 2006 Feb; 76(3): 239-48.
Richter et al., ACS Chem Biol. 2019 Jan 18; 14(1): 37-49.
Salem et al., J Am Soc Nephrol. 2019 Oct; 30(10): 2000-2016.
Shackel et al., Am J Pathol. 2002 Feb; 160(2): 641-54.
Witten et al., J Mol Med. 2018 Aug; 96(8): 765-775.
Zhong et al., Oncol Rep. 2019 Dec; 42(6): 2844-2854.

Also Published As

Publication number Publication date
CL2025001435A1 (es) 2025-08-22
IL320735A (en) 2025-07-01
JPWO2024111560A1 (https=) 2024-05-30
JP7823226B2 (ja) 2026-03-03
TW202430151A (zh) 2024-08-01
PE20251709A1 (es) 2025-07-02
MX2025005556A (es) 2025-06-02
AU2023386923A1 (en) 2025-05-15
CN120569374A (zh) 2025-08-29
WO2024111560A1 (ja) 2024-05-30
CO2025006877A2 (es) 2025-06-06
EP4624465A1 (en) 2025-10-01

Similar Documents

Publication Publication Date Title
JP7051829B2 (ja) Ｄｎｍｔ１の阻害剤としての置換ピリジン
TWI789381B (zh) 雜環化合物
AU2021202973B2 (en) Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity
CN108473498B (zh) 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物
JP6356364B1 (ja) Ａｐｊ受容体のトリアゾールアゴニスト
CN102971311B (zh) 作为gpr119调节剂的二环杂芳基化合物
CN111601799A (zh) 作为Il-17调节剂的稠合咪唑衍生物
JP2017505337A (ja) Ｉｒａｋ４阻害剤としてのインダゾール化合物
JP6434989B2 (ja) ピリジルピペリジン
JP2024521618A (ja) 複素環式化合物
TW201242959A (en) Complement pathway modulators and uses thereof
CN104755465A (zh) 杂环化合物
WO2022228547A1 (zh) 一种膦酰衍生物及其组合物和药学上的应用
TW201414737A (zh) 作爲激酶抑制劑之咪唑并三□甲腈
TW201211053A (en) Spiro compound and drug for activating adiponectin receptor
KR20210151833A (ko) Eed 및 prc2 조절제로서 마크로사이클릭 아졸로피리딘 유도체
TW201240971A (en) Fused heterocyclic compounds
EP4561575A2 (en) Cdk2 inhibitors and methods of using the same
JP7295019B2 (ja) ７－置換１－アリール－ナフチリジン－３－カルボン酸アミドおよびその使用
JP2023523300A (ja) Ｃｃｒ６受容体調節剤としてのアゼチジン－３－イルメタノール誘導体
CN111655680B (zh) 用于治疗代谢突变和纤维化病状及病症的激素受体调节剂
CN110191884A (zh) 取代的6-(1h-吡唑-1-基)嘧啶-4-胺衍生物及其用途
KR20250109234A (ko) Ddr1 키나아제 저해제로서의 화합물 및 의약
IL302542A (en) Pyrazole derivatives as RET KINASE inhibitors
CN107922347A (zh) 新型酰亚胺衍生物及其作为药物的用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)